Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Mediastinal germ cell tumor

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    11 result(s) found for: Mediastinal germ cell tumor. Displaying page 1 of 1.
    EudraCT Number: 2012-004508-36 Sponsor Protocol Number: FM-12-GCT01 Start Date*: 2013-05-04
    Sponsor Name:Fondazione Michelangelo - Avanzamento dello studio e cura dei tumori
    Full Title: Brentuximab vedotin (SGN-35) as salvage therapy for males with advanced and platinum-resistant germ-cell tumors. An open label, single group, Phase 2 trial
    Medical condition: Patients with histologically-confirmed germ-cell cancer with exclusive or prevalent CD30-positive embryonal carcinoma component
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061378 Testicular germ cell cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-004632-38 Sponsor Protocol Number: GCTSK005 Start Date*: 2017-11-09
    Sponsor Name:Národný onkologický ústav
    Full Title: Phase II study of Avelumab in multiple relapsed/refractory testicular germ cell cancer.
    Medical condition: Extracranial primary germ cell cancer, seminoma, or nonseminoma.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061378 Testicular germ cell cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10039956 Seminoma PT
    20.0 100000021189 10029557 Non-seminoma testicular cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SK (Completed)
    Trial results: View results
    EudraCT Number: 2004-000405-22 Sponsor Protocol Number: TE23 Start Date*: 2005-02-25
    Sponsor Name:Medical Research Council
    Full Title: TE23: Randomised Phase II trial of intensive induction chemotherapy (CBOP/BEP) and standard BEP chemotherapy in poor prognosis male germ cell tumours.
    Medical condition: Poor prognosis male germ cell tumours
    Disease: Version SOC Term Classification Code Term Level
    9.1 10043333 Testicular germ cell tumour mixed stage III LLT
    9.1 10015802 Extragonadal primary germ cell tumour mixed stage III LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-004981-42 Sponsor Protocol Number: GCTSK001 Start Date*: 2008-01-17
    Sponsor Name:Narodny onkologicky ustav
    Full Title: Phase II study of sunitinib malate (SUTENT®) in relapsed germ cell tumors in males.
    Medical condition: germ cell tumor
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: SK (Completed)
    Trial results: View results
    EudraCT Number: 2011-001502-10 Sponsor Protocol Number: GCTSK002 Start Date*: 2011-09-28
    Sponsor Name:National Cancer Institute
    Full Title: Phase II study of Everolimus in refractory testicular germ cell cancer.
    Medical condition: refractory metastatic germ cell tumors
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SK (Completed)
    Trial results: View results
    EudraCT Number: 2014-001270-33 Sponsor Protocol Number: GCTSK003 Start Date*: 2015-07-28
    Sponsor Name:Národný onkologický ústav
    Full Title: A treatment strategy of the Use of 1st line Chemotherapy in Patients with Poor-Prognosis Disseminated Non-Seminomatous Germ Cell Tumors based on tumor marker decline: A Phase II Trial of paclitaxel...
    Medical condition: Disseminated Non-Seminomatous Germ Cell Tumors.
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061184 Germ cell cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SK (Completed)
    Trial results: View results
    EudraCT Number: 2013-000286-36 Sponsor Protocol Number: IGR2012/1950 Start Date*: 2014-04-02
    Sponsor Name:Gustave Roussy
    Full Title: A prospective phase II trial of cabazitaxel in male patients with chemotherapy pre-treated metastatic non-seminomatous germ-cell tumors
    Medical condition: patients with pre-treated metastatic and /or primary mediastinal non-seminomatous germ-cell tumors
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-004910-33 Sponsor Protocol Number: PAZOTEST-01 Start Date*: 2012-12-24
    Sponsor Name:ISTITUTO NAZIONALE PER LA CURA TUMORI
    Full Title: Phase II study of single-agent Pazopanib (Votrient) for patients with relapsed or refractory germ-cell tumors (GCT).
    Medical condition: Testicular or extragonadal germ cell tumors.
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10018187 Genitourinary neoplasms malignancy and gender unspecified HLT
    Population Age: Adults Gender: Male
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-001072-13 Sponsor Protocol Number: GETUG13 Start Date*: 2005-10-25
    Sponsor Name:UNICANCER
    Full Title: A risk-adapted strategy of the use of dose-dense chemotherapy in patient with poor-prognosis dissemined non-seminomatous germ cell tumors. GETUG 13 / 0206
    Medical condition: Non-Seminoma Germ Cell Tumor
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male
    Trial protocol: SK (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2021-006638-38 Sponsor Protocol Number: 2021/3282 Start Date*: 2022-05-18
    Sponsor Name:GUSTAVE ROUSSY
    Full Title: A prospective program aiming at improving outcome for young adults with poor-prognosis non seminomatous germ-cell tumors - VAPOR (GETUG T06)
    Medical condition: Non-seminomatous germ-cell tumors (including testis, retroperitoneal and mediastinal primaries) with a disseminated disease (clinical stages II or III according to AJCC 8th edition) and classified ...
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-006326-48 Sponsor Protocol Number: CO43810 Start Date*: 2022-09-27
    Sponsor Name:Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd
    Full Title: A PHASE I/II, OPEN-LABEL, SINGLE-ARM, TWO-PART TRIAL TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND ANTI-TUMOR ACTIVITY OF GLOFITAMAB IN COMBINATION WITH CHEMOIMMUNOTHERAPY IN PEDIATRIC AN...
    Medical condition: CD20 positive B-Cell Non-Hodgkin Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004864 10084346 B-cell non-Hodgkin's lymphoma LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Ongoing) DK (Trial now transitioned) IT (Trial now transitioned) DE (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 04 12:02:48 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA